Clinical Research and Public HealthHematologyImmunologyOncology
Open Access |
10.1172/jci.insight.210272
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Parnell, N. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Cao, X. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Beumer, J. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Braun, T. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Cui, Y. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Fisher, G. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Hou, G. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Holleran, J. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Churay, T. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Rozwadowski, M. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Heider, L. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Vander Lugt, M. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Kitko, C. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Rahrig, A. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Peres, E. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Williams, K. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Talano, J. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Fabrizio, V. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Abusin, G. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Yanik, G. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Magenau, J. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Riwes, M. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Geer, M. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Anand, S. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Ghosh, M. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by
Pawarode, A.
in:
PubMed
|
Google Scholar
|
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by Votruba, K. in: PubMed | Google Scholar
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by
Reddy, P.
in:
PubMed
|
Google Scholar
|
1Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
2Analytical Pharmacology Shared Resource, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA.
3Department of Biostatistics, School of Public Health,
4Department of Dermatology,
5Rogel Cancer Center, and
6Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
7Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
8Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Michigan, Ann Arbor, Michigan, USA.
9Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Vanderbilt Children’s Hospital, Nashville, Tennessee, USA.
10Department of Pediatrics, Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Riley Children’s Health, Indianapolis, Indiana, USA.
11Department of Internal Medicine, Division of Hematology/Oncology/Blood and Marrow Transplantation, Henry Ford Health, Detroit, Michigan, USA.
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematopoietic Cellular Therapy, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
13Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
14Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Children’s Hospital Colorado, Aurora, Colorado, USA.
15Department of Psychiatry, Neuropsychology Program, University of Michigan, Ann Arbor, Michigan, USA.
16Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Find articles by
Choi, S.
in:
PubMed
|
Google Scholar
|
Published September 24, 2026 - More info
BACKGROUND. This prospective, single-arm, multicenter phase I/II trial evaluated vorinostat added to standard graft-versus-host disease (GVHD) prophylaxis in pediatric, adolescent, and young adult (AYA) patients undergoing allogeneic hematopoietic cell transplantation (HCT) from HLA-matched related, HLA-matched unrelated, and haploidentical donors.
METHODS. Patients aged 3–39 years received twice-daily vorinostat with tacrolimus/methotrexate after HLA-matched HCT from day –10 to +30, or with posttransplant cyclophosphamide/tacrolimus/mycophenolate mofetil after haploidentical HCT from day +5 to +30. The primary endpoint was cumulative incidence of grade 2–4 acute GVHD by day +100. All outcomes were based on intention-to-treat analysis.
RESULTS. Forty-three patients were enrolled; median age was 19 years, with 74% receiving HLA-matched and 26% haploidentical HCT. The recommended phase II dose was 60 mg/m2 twice daily. No dose-limiting toxicities, unexpected vorinostat-related serious adverse events, or primary graft failures occurred. Median neutrophil and platelet recovery occurred at 14 and 18 days, respectively. Day +100 grade 2–4 and 3–4 acute GVHD were 14% (95% CI, 5.6%–26%) and 4.7% (95% CI, 0.83%–14%), respectively. One-year overall survival was 88.4% (95% CI, 79.3%–98.5%), relapse 14% (95% CI, 5.6%–26%), nonrelapse mortality 4.7% (95% CI, 0.8%–14%), and GVHD-free/relapse-free survival 55.8% (95% CI, 42.8%–72.8%). Correlative studies demonstrated on-target HDAC activity, with increased histone.
RESULTS. Forty-three patients were enrolled; median age was 19 years, with 74% receiving HLA-matched and 26% haploidentical HCT. The recommended phase II dose was 60 mg/m2 twice daily. No dose-limiting toxicities, unexpected vorinostat-related serious adverse events, or primary graft failures occurred. Median neutrophil and platelet recovery occurred at 14 and 18 acetylation and lower proinflammatory cytokines.
CONCLUSION. These findings support randomized evaluation of vorinostat-based GVHD prophylaxis in pediatric and AYA HCT.
TRIAL REGISTRY. ClinicalTrials.gov NCT03842696.
FUNDING. NIH grants 1R01CA249211, UG1HL069330, 1K24HL156896, and NHLBI Training Grant T32HL007622-36.
Allogeneic hematopoietic stem cell transplantation (HCT) is potentially curative therapy for high-risk hematologic malignancies. Its broader application remains limited by acute graft-versus-host disease (GVHD), a complication driven by donor alloreactivity that can cause substantial early morbidity and mortality and contributes to long-term functional impairment among survivors (1). First-line therapy for established acute GVHD continues to rely on high-dose systemic corticosteroids, yet only approximately half of patients achieve durable responses, and steroid-refractory or -dependent GVHD is associated with poor outcomes and treatment-related toxicities (2). Thus, novel and less toxic prevention strategies remain an urgent priority.
Despite major advances in defining the immunobiology of acute GVHD over the past several decades, prophylaxis has historically centered on calcineurin-inhibitor-based regimens with antimetabolites and related T cell–directed approaches (3). Furthermore, many published studies on GVHD management focus on adults, and assumptions of efficacy are extrapolated to pediatric patients (i.e., children, adolescents, and young adults [AYAs]). However, translating adult regimens to children and AYAs is challenging because of developmental differences that may affect dosing, pharmacokinetics (PK), and adverse event (AE) profiles. This is particularly relevant in younger recipients, in whom growth and development are ongoing and survivorship priorities include quality of life and cognitive health (4).
In recent years, the rapid adoption of HLA-haploidentical transplantation using posttransplant cyclophosphamide (PTCy) has expanded donor availability and produced outcomes comparable to HLA-matched related donor (MRD) and -matched unrelated donor (MUD) transplantation in many adult studies (5–9). This supports the inclusion of haploidentical myeloablative conditioning with PTCy as an important contemporary transplant platform in clinical trial design for GVHD prevention studies.
Histone acetylation is a key epigenetic mechanism that regulates chromatin accessibility and protein function by histone acetyltransferases and histone deacetylases (HDACs) (10). HDACs are aberrantly expressed in many cancers and have been targeted therapeutically (11). Thus, HDAC inhibitors have emerged as an important class of anticancer agents, including FDA-approved therapy for cutaneous T cell lymphoma (12). In preclinical models of allogeneic HCT, HDAC inhibition (suberoylanilide hydroxamic acid or vorinostat) at lower noncytotoxic concentrations suppressed proinflammatory cytokines, modulated antigen-presenting cells, attenuated GVHD-associated tissue injury, and preserved graft-versus-leukemia (13–15).
Building on these observations, we previously reported that adding vorinostat to standard GVHD prophylaxis was safe and feasible in adult HCT studies across MRD and MUD transplantation and both reduced-intensity and myeloablative-conditioning settings. In these studies, vorinostat-based prophylaxis was associated with reduced GVHD without compromising relapse or survival (16, 17). Correlative analyses showed reduced proinflammatory cytokines (18), and neurocognitive assessments identified only mild impairment over time compared with individuals not treated with vorinostat (19). Other HDAC inhibitors, including panobinostat, have also been investigated in adult prophylaxis settings, with encouraging acute GVHD outcomes and no increase in relapse (20). However, pediatric and AYA HCT recipients are clinically distinct, and data supporting HDAC inhibition for GVHD prophylaxis in this population have been lacking. Therefore, the current study was designed to evaluate the safety, feasibility, and recommended phase II dose (RP2D) of vorinostat added to standard GVHD prophylaxis in children and AYAs undergoing allogeneic HCT for hematologic malignancies, to estimate the incidence of acute GVHD, and to characterize PK and pharmacodynamic (PD) profiles of HDAC inhibition. To our knowledge, this is the first prospective, multisite phase I/II trial of HDAC inhibition for GVHD prophylaxis in this population.
Patient characteristics.
Between February 2020 and April 2025, 43 patients were enrolled across 6 centers. All patients were evaluable for safety and for primary, secondary, and exploratory endpoints. Six patients enrolled in phase I; per protocol, the first 3 patients received dose level 0 (45 mg/m2). In the absence of dose-limiting toxicities, 3 subsequently received dose level 1 (60 mg/m2), which was established as the RP2D. An additional 37 patients were enrolled in phase II at the RP2D.
Baseline demographics and clinical characteristics are summarized in Table 1. The findings are reported for the total treated cohort unless otherwise specified. Median age was 19 years (IQR, 9.5–30.5) with 21 participants under 19 years of age and 22 participants 19 years of age or older (Supplemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.210272DS1). Female participants comprised 62.8% of the cohort and 37.2% were male. Most participants reported race as White (83.7%) and ethnicity as non-Hispanic (86%). Underlying diagnoses were primarily acute leukemias. The median infused CD34+ cell dose was 4.55 × 106 cells/kg (IQR, 3.2–6.0). Median donor age was 25 years (IQR, 17.5–28.0), and donors were 60.5% male and 39.5% female. Thirty-two transplants (74%) were HLA-matched and 11 (26%) were haploidentical.
Safety and drug compliance.
No deaths or unexpected serious AEs (SAEs) were considered related to vorinostat. The most frequent SAEs were grade 3 or higher Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0) infection, followed by fever and diarrhea (Supplemental Table 2). AEs were graded and coded per CTCAE v5.0 by System Organ Classes and collected through day 180 (Supplemental Table 3). The most common AEs were due to metabolism and nutrition disorders (e.g., hypomagnesemia, hypoalbuminemia, hypophosphatemia), followed by Investigations (e.g., decrease in platelets, increase in hemoglobin, increase in creatinine) and gastrointestinal disorders (e.g., diarrhea, nausea, abdominal pain). Four patients received less than 50% of planned doses and permanently discontinued because of infection, sinusoidal obstruction syndrome, acute kidney injury, or acute GVHD. Eight additional patients received a median of 63% of planned doses (range, 51.2–78.1), most commonly due to gastrointestinal toxicity. The remaining 31 patients received more than 80% planned doses, with a median of 98% (range, 85.2–100).
Engraftment and graft failure.
Engraftment outcomes are shown in Table 2. Median time to neutrophil engraftment was 14 days (range: 9–25). The cumulative incidence of neutrophil engraftment was 100% by day 28 (95% CI, 91.8%–100%). Median time to platelet engraftment (≥20,000/mm3) was 18 days (range: 6–106). The cumulative incidence of platelet recovery was 72.1% by day 28 (95% CI, 53.9%–82.8%) and 95.3% by day 100 (95% CI, 84.2%–99.4%). Across donor types, neutrophil recovery was uniformly high by day 100, with shorter median time to engraftment in MUD recipients compared with MRD and haploidentical recipients. Platelet recovery showed slower recovery in MRD recipients compared with haploidentical and MUD recipients (Supplemental Table 4). There were no primary graft failures, and engraftment outcomes did not differ notably by age (<19 or ≥19 years; Supplemental Table 5).
Acute and chronic GVHD.
Acute and chronic GVHD outcomes are shown in Table 2 and Figure 1. The prespecified phase II primary endpoint was met in the RP2D expansion cohort. Among the 37 phase 2 participants, the day +100 cumulative incidence of grade II–IV acute GVHD was 16% (95% CI, 6.5%–30%), below the benchmark of 50% used for trial design. The corresponding incidence was similar in the total treated cohort at 14% (95% CI, 5.6%–26%) with 4 cases of grade 2 acute GVHD, isolated to upper gastrointestinal tract involvement only. Severe acute GVHD was uncommon with only 1 case of grade 3 lower gastrointestinal tract and 1 case of grade 4 skin involvement. There was no liver involvement. Grade 2–4 acute GVHD primarily occurred in haploidentical at 9.1% (95% CI, 0.44%–35%) and MUD recipients at 20% (95% CI, 7.1%–38%), and was not observed among MRD recipients (Supplemental Table 4). The incidence was also higher in older participants (≥19 years; 23%; 95% CI, 8%–42%) compared with younger participants (<19 years; 4.5%; 95% CI, 0.3%–20%; Supplemental Table 5).
Figure 1Clinical outcomes. One-year cumulative incidence (%) of (A) acute graft-versus-host disease (GVHD), (B) chronic GVHD, (C) non-relapse mortality (NRM), (D) relapse, (E) GVHD-free, relapse-free survival (GRFS), and (F) overall survival (OS). Cumulative incidence functions were used for acute GVHD, chronic GVHD, NRM, and relapse (A–D), accounting for competing risks; relapse and NRM were treated as competing risks for each other, and relapse and death without prior GVHD were treated as competing risks for GVHD outcomes. GRFS and OS (E and F) were estimated using the Kaplan-Meier method. Shaded areas represent 95% CIs. No formal hypothesis tests were performed for these outcomes.
The cumulative incidence of chronic GVHD requiring immunosuppression therapy (IST) was 9.3% at 6 months (95% CI, 2.9%–20%) and 23% at 1 year (95% CI, 12%–37%), with a median onset at day 185.5 (range, 139–225). This was predominantly observed among MUD recipients (36%; 95% CI, 18%–55%) compared with haploidentical (9.1%; 95% CI, 0.44%–35%), with no cases among MRD recipients (Supplemental Table 4). Rates were similarly higher among older participants (45%; 95% CI, 24%–65%; Supplemental Table 5). Severe chronic GVHD was infrequent (2.3% at 6 months and 1 year; 95% CI, 0.18%–11%) and moderate-to-severe cases occurred in 4.7% by 6 months (95% CI, 0.82%–14%) and 14% by 1 year (95% CI, 5.6%–26%).
Survival, relapse, and GRFS.
Survival and disease outcomes are shown in Table 3 and Figure 1. At 1 year, overall survival (OS) was 88.4% (95% CI, 79.3%–98.5%). Causes of death included relapse (n = 3), pulmonary infection (n = 1), and multiorgan dysfunction (n = 1). There were no deaths related to GVHD. The 1-year GVHD-free, relapse-free survival (GRFS) was 55.8% (95% CI, 42.8%–72.8%). Non-relapse mortality (NRM) was low and stable over time at 4.7% at day 100, 6 months, and 1 year (95% CI, 0.8%–14.0% for each). The cumulative incidence of relapse was 14% at 1 year (95% CI, 5.6%–26.0%). Two of the 7 relapses occurred in MRD recipients (29%; 95% CI, 2.9%–64%) compared with rates of 12% in MUD (95% CI, 2.9%–28%) and 9.1% in haploidentical recipients (95% CI, 0.44%–35%; Supplemental Table 6). While OS was similar across age groups, 1-year GRFS was lower in older participants (40.9%; 95% CI, 24,8%–67.7% vs. 71.4%; 95% CI, 54.5%–93.6%), whereas relapse was higher in younger participants (19%; 95% CI, 5.7%–38% vs. 9.1%; 95% CI, 1.5%–26%; Supplemental Table 7).
PK studies.
Vorinostat PK data were available for 37 patients across both dose levels 0 and 1 and transplant types (Table 4 and Figure 2). One participant with severe renal dysfunction and multiorgan dysfunction was excluded from summary analyses (details provided in Supplemental Figure 2). Because dosing was capped at 100 mg orally twice daily (BID), PK groups were defined according to actual delivered body surface area–normalized (BSA-normalized) dose. Among HLA-matched recipients, vorinostat exposure increased with dose escalation from 45 to 60 mg/m2, with area under the curve (AUC) increasing from 326 to 419 μg/L•h and an apparent clearance of approximately 145 L/h/m2. In contrast, AUC for vorinostat glucuronide and 4-anilino-4-oxobutanoic acid showed minimal change with dose (Supplemental Tables 8–9 and Supplemental Figure 3). In HLA-matched patients, vorinostat clearance variability appeared somewhat lower when normalized to BSA rather than when expressed in absolute terms (coefficient of variation [CV] 41.5% vs. 56.0%, Supplemental Table 10). The exposure for patients with high BSA values appeared to be lower than patients with low BSA values (Supplemental Figure 4).
Figure 2Pharmacokinetic data. Geometric mean and standard deviation (SD) by analyte (vorinostat, glucuronide metabolite, acid metabolite, from left to right), dose level (45 mg/m2, 60 mg/m2), and donor type (HLA-matched or haploidentical) with individual data (open circles).
Compared with HLA-matched recipients, haploidentical recipients had similar dose-normalized vorinostat Cmax but higher half-life and AUC. Dose-normalized metabolite Cmax values were lower and metabolite half-lives were prolonged. However, metabolite AUCs were similar overall, resulting in lower metabolic ratios in haploidentical recipients (Supplemental Tables 8 and 9, and Supplemental Figures 3, 5, and 6).
PD studies.
PD analyses supported target engagement. Acetylated H4–to–total H4 ratios were significantly higher in vorinostat-treated patients than in historical controls, whereas acetylated H3–to–total H3 ratios were higher but not statistically significant (Figure 3). Vorinostat-treated patients also had lower day 30 plasma concentrations of IL-2, IL-4, IL-6, IL-10, Reg3α, HGF, TNFR1, and TNF-α compared with historical controls (Figure 4). Concentrations of IFN-γ, GM-CSF, IL-12p70, ST2, and CD25 did not differ significantly between groups (data not shown). Additionally, the absolute counts and percentages of CD4+, CD8+, CD4+CD25hiCD127–, and FoxP3+CD4+CD25hiCD127– lymphocytes were not different between the groups (Supplemental Figures 7 and 8).
Figure 3Histone H3 and H4 levels at baseline and day 30 after HCT in historical controls and vorinostat-treated patients. Scatter plots represent ratios of individual patient values for acetylated histone H3 (H3K9)/total H3 (A) and acetylated histone H4 (H3K4)/total H4 (B) proteins measured in PBMCs on day 30 after HCT comparing historical controls (blue) and vorinostat-treated patients (red). Between-group comparisons were performed using 2-sided Wilcoxon rank-sum tests. P values are shown in each panel. Box bonds: 75% quantiles, median, 25% quantiles. The whiskers are observed values. No outliers as it is log transformed
Figure 4Plasma cytokines on day 30 after transplantation. All measurements were obtained on day 30 after transplantation. Blue squares denote historical controls (similarly treated patients who did not receive vorinostat) and red circles denote patients who received vorinostat. Horizontal black lines indicate the median and error bars depict the IQR; sample sizes are shown beneath each group. Panels show plasma concentrations of (A) IL-2, (B) IL-4, (C) IL-6, (D) IL-10, (E) Reg3α, (F) HGF, (G) TNF-α, and (H) TNFR1, assessed by multiplex (Luminex) immunoassay. Between-group comparisons on day 30 were performed using analysis of covariance (ANCOVA) on log-transformed biomarker levels, with treatment group as the primary predictor and the corresponding baseline biomarker level included as a covariate. Adjusted fold changes (Adj FC) were obtained by exponentiating the treatment-group coefficients; adjusted P values are shown in each.
In this prospective, multisite phase I/II trial, vorinostat added to standard GVHD prophylaxis was safe in children and AYAs undergoing allogeneic HCT across HLA-matched and haploidentical donor settings. The RP2D was 60 mg/m2 twice daily. The cumulative incidence of grade 2–4 acute GVHD by day 100 was low at 14%, and severe grade 3–4 acute GVHD uncommon. These clinical findings were associated with PD findings consistent with on-target HDAC inhibition, including increased H3/H4 acetylation and lower day 30 levels of several proinflammatory cytokines compared with historical controls. Collectively, these findings extend our prior adult experience with vorinostat-based GVHD prophylaxis to a younger HCT population.
The observed day 100 grade 2–4 acute GVHD incidence compares favorably with expectations that informed the trial design. When this protocol was developed, our institutional pediatric/AYA benchmark for myeloablative transplantation with standard prophylaxis was approximately 50% for acute GVHD (21–24). Although comparisons across trials must be made cautiously given differences in donor types, conditioning, graft source, and supportive care, the low incidence of grade 2–4 acute GVHD, together with the very low rate of severe grade 3–4 acute GVHD, is consistent with clinically meaningful activity with the addition of vorinostat. Most of the cases were limited to upper gastrointestinal tract involvement, responsive to first-line corticosteroid therapy. Liver involvement was not observed, and only 2 patients developed severe acute GVHD (grade 3 lower GI GVHD and stage 4 skin involvement).
Translating adult regimens to younger recipients may be complicated by differences in toxicity susceptibility. Nonetheless, the SAE and AE profiles observed in the current study were consistent with our prior studies in both related donor, reduced intensity conditioning and unrelated donor, myeloablative conditioning settings (16, 17). Vorinostat administration was feasible to administer with most participants achieving high adherence and median compliance of 98% among those without early discontinuation. Among participants with reduced compliance, missed doses were most commonly related to gastrointestinal disturbances, including nausea, diarrhea, similar to findings reported in adult GVHD prevention studies of vorinostat (16, 17) and panobinostat (20). A minority of patients discontinued vorinostat at the treating physician’s discretion in the setting of transplant-related complications and overall clinical complexity. Overall, the safety profile was acceptable, with no unexpected SAEs or deaths attributed to vorinostat. The most frequent SAEs were infections, fever, and diarrhea, events common in myeloablative HCT.
Hematopoietic recovery is an important benchmark when adding new agents to standard GVHD prophylaxis regimens. In this study, neutrophil recovery occurred in all patients by day +28, and platelet recovery exceeded 95% by day +100. This is particularly relevant because strategies intended to reduce acute GVHD may carry potential trade-offs, including impaired engraftment or immune reconstitution, increased infection risk, or increased relapse (3). Acknowledging the modest sample size and limited follow-up, these data did not suggest an increased risk of relapse or infection in this population, including across donor types. The cumulative incidence of relapse was 14% at 1 year, NRM remained low at 4.8% at 1 year, and no deaths were attributable to GVHD. In addition, despite reported poor graft function or graft failure rates of 5%–10% in some PTCy-based transplant studies (9, 25, 26), no graft failures were observed in this study. Together with low NRM and no apparent early signal for excess relapse, these findings support the feasibility of adding vorinostat across donor platforms.
Chronic GVHD remains an important late complication, particularly in children and AYAs, for whom long-term functional outcomes and quality of life are important survivorship considerations. In this study, chronic GVHD requiring IST occurred in 9.3% of patients by 6 months and 23% by 1 year. However, moderate-to-severe chronic GVHD was uncommon, and all cases occurred in young adults aged 19–35 years, with no cases among pediatric patients 18 years or younger. In the context of low relapse, NRM, and infrequent severe acute and chronic GVHD, 1-year GRFS and OS were encouraging at 55.8% and 88.4%, respectively. These outcomes compare favorably with recent reports of pediatric and young adult patients undergoing MRD, MUD, or PTCy-based haploidentical donor transplantation (7–9, 27, 28), such cross-study comparisons should be interpreted cautiously due to cohort heterogeneity.
A strength of this study is the integration of correlative PK/PD analyses. The day 30 plasma biomarker reductions observed in this study, specifically in key inflammatory and mucosal injury–associated cytokines, extend and partially reproduce the antiinflammatory effects observed in our previous vorinostat trials. Across these cohorts, variable biomarker profiles, such as ST2, likely reflect differences in conditioning intensity, donor type, sample timing, and assay platforms. Importantly, this study provides the first characterization to our knowledge of vorinsotat’s PD effects in the haploidentical donor setting, although small sample sizes and historical control comparisons limit direct analyte-level comparisons.
Vorinostat clearance in children and AYAs was 131 L/h/m2, corresponding to 227 L/h when normalized to a standard BSA of 1.73 m2, which was similar to prior adult vorinostat clearance estimates from our group of 271 L/h and 194 L/h (12, 29). Vorinostat AUC0–12 values of approximately 400 μg/L•h in our twice-daily dosing would correspond to an estimated AUC0–24 of 800 μg/L•h (29). This exposure is at the lower end of the approximately 1250 μg/L•h AUC reported with 300 mg and below the approximately 1660 μg/L•h expected with 400 mg, the approved dose of vorinostat for cutaneous T cell lymphoma (30). Consistent with prior reports, we observed substantial interpatient variability in oral vorinostat pharmacokinetics, with geometric SD approximately 1.5–2 and CVs often greater than 50%. Exposures in this study were roughly half of those observed with single-agent vorinostat in adults receiving 400 mg daily. This was expected and is consistent with our prior adult GVHD prevention trials, in which vorinostat was administered at approximately half the approved oncology dose (16, 17). This lower-exposure approach is relevant in the HCT setting because approved oncology doses have been associated with bone marrow suppression, particularly thrombocytopenia (30, 31), which is undesirable during posttransplant hematopoietic recovery.
Vorinostat concentrations of 100–200 nM have been reported to reduce cytokine production in human and murine immune cells (32), corresponding to approximately 26–52 μg/L. In murine models, antiinflammatory effects have been observed after 10–25 mg/kg oral dosing (32), and 35 mg/kg intraperitoneal dosing reduced GVHD (13), with reported plasma concentrations of 100–900 μg/L (33, 34). Concentrations achieved in our study overlapped with these biologically active ranges and, together with evidence of histone acetylation, support pharmacologic target engagement. Exposure-response relationships with clinical GVHD outcomes could not be established, likely because of the low number of GVHD events and modest sample size. Although reduced variability in clearance after BSA normalization is consistent with the rationale for BSA-based dosing, patients with larger BSA values appeared to have lower vorinostat exposure, likely due to the twice-daily dose cap. At the 60 mg/m2 dose level, this cap is reached at a BSA of approximately 1.67 m2, above which the delivered BSA-normalized dose is reduced.
Haploidentical recipients appeared to have a longer vorinostat half-life and higher dose-normalized vorinostat AUC compared with HLA-matched recipients. The HLA-matched half-life, 1.4–1.9 hours, aligns with adult literature values of 1.4, 1.5, and 1.8 hours (12, 29, 35), whereas the half-life in haploidentical recipients was longer, approximately 2.9 hours. Similar vorinostat Cmax despite longer half-life and higher AUC suggest that these differences may reflect reduced clearance rather than altered absorption. The metabolite profile, lower metabolite Cmax, longer half-life, and similar AUC, may also suggest reduced formation clearance of both metabolites. Interpretation of these findings is complicated by differences between haploidentical and HLA-matched recipients in treatment timing and co-administered therapies. Haploidentical recipients initiated vorinostat on day +5, underwent PK sampling on day +10, and received concurrent PTCy, tacrolimus, and mycophenolate mofetil (MMF), whereas HLA-matched recipients initiated vorinostat on day –10, underwent PK sampling on day +1, and received concurrent tacrolimus and methotrexate. Whether the approximately 40% difference in AUC is clinically meaningful remains uncertain, particularly given the substantial overlap in exposures between groups. Future studies with larger sample sizes and paired PD readouts, such as histone acetylation and cytokine modulation, may help determine whether these PK differences translate into meaningful differences in target engagement or downstream cytokines across donor platforms.
Despite our encouraging findings, this study has several limitations. The single-arm, open-label design and use of historical controls introduce potential bias and limit causal inference. The inclusion of broad donor types increased trial accessibility and may broaden applicability (36), but in the setting of a modest sample size, this constrained our subgroup analyses. In addition, the underrepresentation of some racial and ethnic groups of the cohort may affect generalizability.
In conclusion, the low incidence of acute GVHD observed in this single-arm study is encouraging. The historical acute GVHD rate was used for the phase I/II design rather than as a matched concurrent comparator. Comparisons with published cohorts should be interpreted cautiously given differences in patient age, disease risk and status at transplant, graft source, donor type, conditioning regimen, GVHD prophylaxis, supportive care, and calendar period. Nonetheless, vorinostat combined with standard GVHD prophylaxis was feasible and had an acceptable safety profile in children and AYAs undergoing myeloablative conditioning HCT across HLA-matched and haploidentical settings. The observed low incidence of acute GVHD was associated with on-target HDAC inhibition and reduced inflammatory markers. Together with timely neutrophil and platelet recovery, no primary graft failures, low NRM, and acceptable relapse rates, these findings provide preliminary support for studying further in a randomized trial.
Sex as a biological variable
Our study examined male and female hematopoietic transplant recipients, and similar findings are reported for both sexes.
Study design
This phase I/II prospective, multisite, open-label clinical trial evaluated vorinostat combined with standard GVHD prophylaxis in children and AYAs undergoing myeloablative conditioning allogeneic HCT from MRDs, MUDs, or haploidentical donors (Supplemental Figure 1). Phase I used a standard 3+3 dose-escalation design to establish the maximum tolerated dose (MTD)/RP2D of vorinostat administered orally BID in combination with standard GVHD prophylaxis. Planned dose levels were 30, 45, and 60 mg/m2 BID (maximum 100 mg BID), with enrollment starting at 45 mg/m2 and dose escalation or de-escalation determined by cohort dose-limiting toxicities. The phase II primary analysis population consisted of the 37 participants enrolled to the expansion cohort after RP2D determination. The primary endpoint was the cumulative incidence of grade 2–4 acute GVHD in this cohort. Safety and secondary clinical outcomes were summarized in all enrolled and transplanted participants.
Eligibility criteria
Eligible patients were 3–39 years old with a hematologic malignancy and were candidates for myeloablative allogeneic HCT. Additional eligibility criteria included Karnofsky/Lansky performance score of 70% or higher, life expectancy of 6 months or longer, and adequate baseline organ function. Eligible diagnoses included acute or chronic leukemia in morphologic remission (no circulating blasts and <5% bone marrow blasts), myelodysplastic syndrome, or mature B cell lymphoma in remission. Donor selection followed standard high-resolution HLA typing. For MRD and MUD transplants, an HLA-8/8 allelic match at HLA-A, -B, -C, and -DRB1 by high-resolution typing was required. For haploidentical transplants, donors were required to have 2–4 mismatches using HLA-A, -B, -C, and -DRB1; 2–5 mismatches (with HLA-DQB1), and 2–6 mismatches (with HLA-DPB1). Graft sources included bone marrow or peripheral blood stem cells.
Conditioning regimens and GVHD prophylaxis
Matched donor (MRD/MUD) transplantation. Conditioning regimens included fludarabine/busulfan (FluBu), cyclophosphamide (Cy)/total body irradiation (TBI), CyTBI/etoposide (VP-16), and Flu/melphalan. Standard GVHD prophylaxis included tacrolimus (initiated day –3; target trough 8–12 ng/mL) plus methotrexate (initiated on day 1). Methotrexate was administered on days 1, 3, 6, and 11; tacrolimus taper was recommended beginning on day 100 in the absence of active GVHD. Vorinostat was administered day –10 through day 30.
Haploidentical transplantation. Haploidentical conditioning regimens included fludarabine/TBI, busulfan/Cy, CyTBI, FluCyTBI, and FluBu. GVHD prophylaxis consisted of 50 mg/kg PTCy on days 3 and 4, tacrolimus beginning day 5 (target trough 8–12 ng/mL) and taper recommended beginning day 100 in the absence of GVHD and MMF beginning day 5 through day 35. Vorinostat was administered from day +5 through day +30.
AE reporting
Toxicities were graded using CTCAE v5.0. Neutrophil engraftment was defined as the first of 3 consecutive days with an absolute neutrophil count (ANC) of 500/μL or higher, and platelet engraftment as the first of 3 consecutive days with a platelet count of 20,000 cells/μL or higher without platelet transfusion in the preceding 3 days. Primary graft failure was defined as failure to achieve an ANC of 500 cells/μL or greater by day +28. Secondary graft failure was defined as initial neutrophil engraftment followed by a decline in ANC to less than 500 cells/μL that was not attributable to infection, disease relapse, or medications.
Because of potential interactions between vorinostat and conditioning-related toxicities early after transplantation, the protocol required holding vorinostat for any grade 4 or higher non-hematologic toxicity occurring between initiation of vorinostat and day 7 after HCT. Vorinostat could be resumed after recovery, following a minimum 7-day interruption; persistent grade 4 or higher toxicity without recovery within protocol-specified timelines required permanent discontinuation. If acute GVHD developed, continuation of vorinostat at full dose was permitted at the treating physician’s discretion.
Supportive care therapies (e.g., anti-infectives, electrolyte replacement, and blood product transfusions) were administered per institutional guidelines.
Clinical assessments
Acute GVHD was graded weekly with modified Glucksberg criteria (37), and chronic GVHD using the 2014 NIH consensus criteria (38). Hematopoietic recovery, GVHD, relapse, NRM, GRFS, and OS outcomes were assessed through 1 year after transplantation.
Correlative studies
To evaluate PD and PK activity of HDAC inhibition, peripheral blood samples were collected at baseline and at day +30 after transplantation with routine clinical blood draws, processed, frozen, and banked. PK sampling was performed at steady state on the protocol-defined PK day (day 1 for HLA-matched recipients and day 10 for haploidentical recipients), with serial samples collected before and after an observed oral dose, as described below. PD and cytokine studies were performed on day +30, including measurement of histone acetylation (H3 and H4) in peripheral blood mononuclear cells (PBMCs) and plasma cytokines/biomarkers, as described below. As controls for correlative analyses, cryopreserved samples from healthy donors and historic transplant recipients treated with comparable conditioning and GVHD prophylaxis without vorinostat were analyzed.
Histone extraction
Total core histones were extracted from PBMCs (2–5 × 106 cells) using the Histone Extraction Kit (ab221031, Abcam), according to the manufacturer’s standard protocol. Cell pellets were washed with ice-cold phosphate-buffered saline (PBS) and centrifuged at 300g for 5 minutes at 4°C. Pellets were resuspended in 200 μL pre-extraction buffer supplemented with protease inhibitor cocktail and DTT and incubated on ice for 10 minutes. After centrifugation at 100g for 2 minutes at 4°C, the supernatant was discarded, and the histone-containing pellet was resuspended in 200 μL. Samples were incubated on ice for 30 minutes to promote transfer of histones into the soluble fraction and then clarified by centrifugation at 10,000g for 2 minutes at 4°C. The histone-rich supernatant was transferred to a fresh tube and neutralized with 20 μL neutralization buffer. Total protein concentration was quantified using the Qubit Protein Assay. Histone extracts were used immediately or stored in aliquots at –80°C until capillary electrophoresis immunoassay.
Measurement of total and acetylated histones H3 and H4
PBMC histone extracts and standards were separated and quantified by capillary electrophoresis immunoassay using the proteinSimple Jess instrument with 4–40 kDa separation modules, according to the manufacturer’s instructions (39). Antibodies included those against histone H3 (97175, Cell Signaling Technology), acetyl-histone H3K9 (96495, Cell Signaling Technology), histone H4 (25925, Cell Signaling Technology), and acetyl-histone (139445, Cell Signaling Technology).
Signal intensities for histone modifications and total histone proteins were quantified using capillary electrophoresis immunoassay and analyzed with ProteinSimple Compass software (Bio-Techne). For each sample, integrated peak areas were obtained for target bands and for the corresponding molecular weight ladder controls, and normalized to the samples’ protein concentration. For each sample, the H3K9 signal intensity was normalized to total H3 protein, and the H4K12 signal intensity was normalized to total H4 protein. A final ratio was then calculated by dividing the posttreatment values by the baseline values for each individual’s sample. These normalized ratios were subsequently used for graphical presentation.
Plasma cytokines
Plasma concentrations of CD25, GM-CSF, HGF, IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17, Reg3α, ST2, TNF-α, and TNFR1 were measured using Luminex multiplex assay kits (Bio-Techne/R&D Systems, LXSAHM-16) according to the manufacturer’s protocol. Samples were diluted to fall within the linear range of the standard curve and read on a microplate reader.
Phenotype of T lymphocytes
Flow cytometry standard files were acquired on a Sony ID7000 Spectral Analyzer and analyzed using FlowJo software (Waters Corporation). Absolute CD4+, CD8+ and regulatory T cell counts were calculated by multiplying the absolute lymphocyte count by the corresponding percentages of CD4+CD8–, CD4–CD8+, and CD4+CD25+CD127– cells, respectively, within the lymphocyte gate. The lymphocyte gate was confirmed by back-gating on CD4+ cells. The following reagents/antibodies were used: Fixable Viability Dye eFluor 780 (eBioscience); anti-human CD4 BV421, clone OKT4 (BioLegend); anti-human CD8a-PE, clone HIT8a (BioLegend); anti-human CD25-Alexa Fluor 488, clone BC96 (BioLegend); anti-human CD127-PerCP/Cy5.5, clone A019D5 (BioLegend); and anti-human Foxp3-PE/Dazzle 594, clone 206D (BioLegend).
PK
PK sampling was performed at steady state before and at 0.5, 1, 2, 3, 4, 6, and 12 hours following an observed oral dose of vorinostat. For HLA-matched recipients, the PK day was day +1 (the day after stem cell infusion). For haploidentical recipients, the PK day was day +10. At each time point, 2 mL of peripheral blood was collected in red-top vacutainer tubes. Serum was isolated and stored at –70°C until analysis.
Vorinostat and its glucuronide and 4-anilino-4-oxobutanoic acid metabolites were quantified in serum using a previously published, validated LC-MS/MS assay (40). As doses were capped at an absolute dose of 100 mg BID, some participants assigned to the 60 mg/m2 dose level received an actual BSA-normalized dose closer to 45 mg/m2. For PK analyses, participants were grouped by actual delivered BSA-normalized dose rather than assigned protocol dose level. PK parameters were estimated using standard noncompartmental methods with Phoenix WinNonlin (Certara). Statistical testing was performed with RStudio (version 2025.09.1) (https://www.r-studio.com/downloads/RStudio9.exe).
Statistics
All enrolled and transplanted participants were included in analyses of safety and clinical outcomes. When the study protocol was developed (early 2018), the cumulative incidence of grade 2–4 acute GVHD by day +100 among children and AYAs receiving myeloablative conditioning and standard GVHD prophylaxis at our institution was estimated to be 50%, consistent with published literature (21–24). The phase II sample size of 37 patients provided 80% power, using a 2-sided α = 0.05, to detect a reduction in day 100 grade 2–4 acute GVHD from 50% to 28%. Safety analyses included all enrolled and transplanted recipients. Clinical outcomes are summarized for the total treated cohort, with phase-specific estimates reported to preserve the prespecified phase II primary analysis.
OS was estimated using the Kaplan-Meier method from the date of transplantation to either death from any cause or end of follow-up (day 365). Cumulative incidence functions accounting for competing risks were used to estimate relapse, NRM, and GVHD using the Fine-Gray method. Relapse and NRM were treated as competing risks for each other, and relapse and death without GVHD were treated as competing risks for GVHD outcomes. Estimates are reported with 95% CIs. GRFS was defined as time to first occurrence of grade 3–4 acute GVHD, systemic therapy requiring chronic GVHD, relapse, or death (41). Descriptive statistics were used to summarize baseline and transplant characteristics; no formal hypothesis testing was prespecified for subgroup comparisons, which were considered exploratory. Statistical analyses were performed using R version 4.3. Statistical significance was defined as a P value of less than 0.05.
Cytokine concentrations were analyzed on the log-transformed scale because of the right-skewed distribution of the raw measurements. For between-group comparisons on day 30, analysis of covariance (ANCOVA) models were fitted with log-transformed day 30 biomarker levels as the dependent variable, treatment arm as the primary predictor, and corresponding log-transformed baseline biomarker levels included as covariates. Adjusted group differences were summarized as ratios by exponentiating model coefficients from the log-scale analyses. For visualization, individual biomarker values were displayed on a logarithmic scale with median and IQR overlays.
Study approval
The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013) and approved by the U-M Medical School Institutional Review Board, which served as the single IRB for the multisites (HUM001866659). Additionally, the trial was registered on ClinicalTrials.gov (NCT03842696). Investigational New Drug (IND) authorization was obtained from the US FDA. Written informed assent and consent was obtained in accordance with the Declaration of Helsinki.
Data availability
The study protocol and data generated or analyzed during this study are available from the corresponding author on reasonable request. Values for all applicable figure panels, including values for all data points shown in graphs and values behind any reported means, are provided in the accompanying Supporting Data Values file.
Author contributions.
NP drafted the manuscript, organized the data, and created figures and tables under the supervision of SWC. XC performed the data cleaning, processing, and analyses under the supervision of TB and SWC. TB, PR, and SWC designed the study, coordinated the study, and handled the regulatory aspects of the study. MR and TC supervised study staff in all study-related tasks (e.g., recruitment, enrollment, ordering PD samples, ordering PK samples). MVL, GA, GY, JM, MM, MG, CK, KW, SA, MG, AP, JAT, AR, and VF recruited and enrolled participants, reviewed adverse events and serious adverse events, and completed case report forms where applicable. All authors participated in monthly data review calls, participated in the writing and reviewing of the manuscript, including tables, figures, and supplemental data.
AI disclosure.
The authors declare that AI (U-M GPT) was used in editing of the manuscript for grammar and clarity checks. The authors assume full responsibility for ensuring the integrity and accuracy of AI output presented in this article.
Conflict of interest.
The authors have declared that no conflict of interest exists.
Funding.
This study was supported by the following:
This work is the result of NIH funding, in whole or in part, and is subject to the NIH Public Access Policy. Through acceptance of this federal funding, the NIH has been given a right to make the work publicly available in PubMed Central.
We thank the patients and families who participated in the study. We wish to thank the Multi-Site Oncology-Clinical Trials Unit (O-CTSU) team, particularly Aubrie Andrews, Sheryl Morgan, and Sabrina Hargrove, and Suzanne Miesterfield for their collaboration, including during the early period of the COVID-19 pandemic when the trial began. We also thank the Choi Lab coordinators and the multisite coordinators over the past 5 years who helped with recruitment, enrollment, onboarding, and follow-up of all study-related tasks.
Address for correspondence. Sung Won Choi, 1500 E. Medical Center Drive, D4115 Medical Professional Building, Ann Arbor, Michigan 48109, USA. Email: sungchoi@med.umich.edu.
Copyright: © 2026, Parnell et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.
Reference information: JCI Insight. 2026;11(21):e210272.https://doi.org/10.1172/jci.insight.210272.